European Journal of Internal Medicine
Volume 18, Issue 5 , Pages 400-404 , September 2007

Economic evaluation of assistance to HIV patients in a Spanish hospital

  • M. Velasco

      Affiliations

    • Sección Infecciosas, Unidad de Medicina Interna, Fundación Hospital Alcorcón, Spain
    • Corresponding Author InformationCorresponding author. Sección Infecciosas, Unidad de Medicina Interna, Fundación Hospital Alcorcón, C/Budapest n°1, 28922, Alcorcón, Madrid, Spain. Tel.: +34 91 621 9513; fax: +34 91 621 9905.
    • ,
  • J.E. Losa

      Affiliations

    • Sección Infecciosas, Unidad de Medicina Interna, Fundación Hospital Alcorcón, Spain
    • ,
  • A. Espinosa

      Affiliations

    • Sección Infecciosas, Unidad de Medicina Interna, Fundación Hospital Alcorcón, Spain
    • ,
  • J. Sanz

      Affiliations

    • Hospital Príncipe de Asturias, Spain
    • ,
  • G. Gaspar

      Affiliations

    • Hospital Universitario de Getafe, Spain
    • ,
  • M. Cervero

      Affiliations

    • Hospital Severo Ochoa, Leganés, Spain
    • ,
  • R. Torres

      Affiliations

    • Hospital Severo Ochoa, Leganés, Spain
    • ,
  • E. Condes

      Affiliations

    • Hospital de Móstoles, Spain
    • ,
  • C. Barros

      Affiliations

    • Hospital de Móstoles, Spain
    • ,
  • V. Castilla

      Affiliations

    • Sección Infecciosas, Unidad de Medicina Interna, Fundación Hospital Alcorcón, Spain

Received 22 May 2006 ,Revised 2 November 2006 ,Accepted 15 December 2006.

References 

  1. Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002;7(4):257–266
  2. Walensky R, et al. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston. February. 2005;[Abstract 143LB]
  3. Velasco M, Gomez A, Fernandez C, Perez-Cecilia E, Tellez MJ, Roca V, et al. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. HIV Med. 2000;1(4):246–251
  4. Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retrovir. 1999;15(6):499–508
  5. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824–831
  6. Sendi P, Palmer AJ, Gafni A, Battegay M. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. PharmacoEconomics. 2001;19(7):709–713
  7. Krentz H, Auld C, Gill J for the HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995–2001. CMAJ. 2003;169(2):106–110
  8. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344(11):817–823
  9. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999;13(8):963–969
  10. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11(12):F101–F105
  11. Stoll M, Claes C, Schulte E, Graf von der Schulenburg JM, Schmidt RE. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. 2002;7(11):463–471
  12. Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F, Leone L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy. 2003;65(3):261–267
  13. Le Pen C, Rozenbaum W, Downs A, Maurel F, Lilliu H, Brun C. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach. HIV Clin Trials. 2001;2(2):136–145
  14. Rodriguez-Vidigal FF, Habernau A. Cause of hospitalization in patients with human immunodeficiency virus infection in a rural area. Role of chronic liver disease. Enferm Infecc Microbiol Clin. 2004;22(3):138–141
  15. Jaen A, Casabona J, Esteve A, Miro JM, Tural C, Ferrer E, et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc ). 2005;124(14):525–531
  16. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001. AIDS. 2004;18(18):2411–2418

PII: S0953-6205(07)00150-1

doi: 10.1016/j.ejim.2006.12.013

European Journal of Internal Medicine
Volume 18, Issue 5 , Pages 400-404 , September 2007

Article Tools

* Image Usage & Resolution